ALK and non-small cell lung carcinoma: In the phase II EXP-3B arm of NCT01970865 trial, named ALK-positive patients with disease progression following one previous non-crizotinib ALK tyrosine kinase inhibitor with any number of chemotherapy regimens, lorlatinib demonstrated significant intracranial and overall activity in subsequent therapy for advanced NSCLC individuals (28).